Key Highlights
- Tozorakimab successfully achieved its primary endpoint in AstraZeneca’s Phase III MIRANDA clinical trial for COPD patients
- The investigational drug demonstrated significant reduction in moderate-to-severe COPD exacerbations compared to placebo across both former and current smoking populations
- Trial participants received 300mg doses of tozorakimab administered bi-weekly alongside their standard treatment regimen
- These positive outcomes complement earlier successful results from the OBERON and TITANIA Phase III studies announced in March
- The pharmaceutical company intends to file data with regulatory agencies and share complete findings at a future medical conference
AstraZeneca’s investigational chronic obstructive pulmonary disease medication tozorakimab has successfully achieved another Phase III milestone, strengthening the drug’s expanding portfolio of positive clinical outcomes.
The MIRANDA clinical study demonstrated that tozorakimab delivered a statistically meaningful decrease in the annual rate of moderate-to-severe COPD exacerbations when compared against placebo. These encouraging outcomes were observed in both the core population of former smokers and the expanded cohort that encompassed current smokers.
Study participants were administered either tozorakimab 300mg or a placebo bi-weekly as an adjunct to their current standard care protocols. The trial specifically recruited patients who continued to suffer from exacerbations despite maintaining their prescribed inhaled medication therapies.
The medication’s safety characteristics remained aligned with previous clinical studies, with the treatment generally demonstrating good tolerability among participants.
Third Consecutive Phase III Win
This marks another successful chapter in tozorakimab’s clinical development journey. Earlier this year in March, AstraZeneca reported favorable outcomes from two additional Phase III studies — OBERON and TITANIA — which evaluated the medication using a monthly dosing regimen.
MIRANDA employed a bi-weekly administration protocol, providing AstraZeneca with comprehensive efficacy data spanning multiple dosing intervals.
The medication represents a potentially first-in-class monoclonal antibody designed to target interleukin-33, a key protein that plays a role in inflammatory processes. This unique mechanism of action differentiates it from currently available inhaled COPD medications.
Frank Sciurba, a professor at the University of Pittsburgh and chief investigator of the LUNA program, said the results “add to the growing body of evidence that indicates tozorakimab delivered meaningful clinical benefits for COPD patients who urgently need new treatment options.”
Chronic obstructive pulmonary disease impacts approximately 400 million individuals across the globe and ranks as the world’s third most common cause of mortality. More than half of affected patients continue experiencing exacerbations despite adhering to standard inhaled therapy regimens — a therapeutic void that tozorakimab may potentially address.
Looking Ahead
AstraZeneca has announced plans to file the MIRANDA trial data with health regulatory bodies. The pharmaceutical company will also unveil the complete findings at a forthcoming medical conference, though specific timing and venue details have yet to be disclosed.
In addition to COPD applications, tozorakimab is currently undergoing evaluation in Phase III clinical programs for severe viral lower respiratory tract infections and Phase II investigations for asthma treatment.
The MIRANDA study outcomes encompassed patients spanning all blood eosinophil levels and all degrees of lung function impairment, potentially expanding the eligible patient base that could benefit from this therapy.
AstraZeneca has not yet disclosed a definitive timeline for regulatory submissions.
